Floatz logo

DACLIZUMAB

DiGeorge Anomaly

Sumitomo Pharma Switzerland GmbHmonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the DiGeorge Anomaly cohort.

Asset / SponsorPhaseRating
Thiotepa
Washington University School of Medicine
Phase 2CCC
Evomela
Paul Szabolcs
Phase 2CCC
Fludarabine
Paul Szabolcs
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Paul Szabolcs
Phase 2CCC
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
Rabbit Anti-Thymocyte Globulin
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
TACROLIMUS
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
CYCLOSPORIN A
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC

Same molecule, other indications

DACLIZUMAB is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →
HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)Dormant
BB
Indicative ·
68 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →